{"filings":[{"id":471718,"accession_number":"0001104659-26-062640","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-05-15T20:31:48+00:00","items":["5.07"],"status":"ready","headline":"Certara stockholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III directors elected: Bedi 121.7M for, McLean 99.9M for (22.9M withheld), Resnick 121.7M for.","RSM US LLP ratified as independent auditor for FY 2026: 141.7M for, 0.76M against.","Non-binding say-on-pay approved: 120.3M for, 2.3M against, 0.11M abstain.","Notable: ~22.9M shares withheld from director McLean, indicating shareholder dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95900,"accession_number":"0001827090-26-000017","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $106.9M (+1% YoY); software revenue $49.7M (+7%), services revenue $57.2M (-4%).","Net loss $8.8M vs net income $4.7M YoY; adjusted EBITDA $31.7M (-9% YoY); diluted EPS -$0.06 vs +$0.03.","Closed sale of Regulatory Writing/Medical Writing business to Veristat on May 8 for $85M cash + $15M escrow + up to $35M earn-out.","Updated 2026 guidance: revenue growth 0-4% excluding the divested business; software bookings up 20% to $48.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":106915000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95899,"accession_number":"0001104659-26-046358","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Certara sells Regulatory & Medical Writing business to Veristat for up to $135M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $100M plus up to $35M earn-out based on future performance.","Sold business generated $50M revenue and $17M adjusted EBITDA in 2025, employing ~220 people.","Transaction expected to close in Q2 2026 subject to customary conditions.","Certara will update 2026 guidance after close; proceeds to be deployed for MIDD platform growth.","Sale sharpens focus on Model-Informed Drug Development and AI-integrated modeling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109318,"accession_number":"0001104659-26-037798","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Cynthia Collins resigns from Certara board, effective May 14, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cynthia Collins notified her resignation as Class II director and Audit Committee member, effective at the 2026 annual meeting.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Board will reduce to nine members after her departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109317,"accession_number":"0001827090-26-000008","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q4 revenue $103.6M (+3%), net loss $5.9M; appoints Jon Resnick CEO; FY26 rev growth 0-4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $103.6M (+3% YoY); software revenue $46.4M (+10%), services $57.3M (-1%).","Q4 net loss $5.9M vs net income $6.6M in Q4 2024; adj. EBITDA $32.5M (-3% YoY).","FY 2025 revenue $418.8M (+9%); adj. EBITDA $134.5M (+10%) with 32% margin.","FY 2026 guidance: revenue growth 0-4%, adj. EBITDA margin 30-32%, adj. diluted EPS $0.44-$0.48.","Jon Resnick appointed CEO and board member effective January 1, 2026, succeeding previous CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":418838000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125803,"accession_number":"0001104659-25-120096","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints Jon Resnick as CEO effective Jan 1, 2026; Feehery departs Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Resnick, former IQVIA US/Canada President, named CEO effective Jan 1, 2026; William Feehery steps down Dec 31, 2025.","Resnick receives $750k base salary, 100% target bonus, $6.5M make-whole RSU, and LTI awards of $4M (2025) and $8M (2026).","Feehery to serve as external advisor at $20k/month consulting fee; post-employment benefits per existing agreement.","Resnick appointed as Class III director with term expiring at 2026 annual meeting.","Company reaffirms full year 2025 financial outlook as disclosed Nov 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125802,"accession_number":"0001827090-25-000046","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 2025 revenue $104.6M (+10% YoY); net income $1.5M vs loss; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $104.6M, +10% YoY; software $43.8M (+22%), services $60.8M (+3%).","Net income $1.5M vs net loss $1.4M in Q3 2024; adjusted EBITDA $35.2M (+7%).","Full-year 2025 guidance updated: profitability targets raised, revenue range narrowed.","Launched new software CertaraIQ for QSP modeling to expand biosimulation use.","CFO noted spending hesitancy in some services but strong QSP demand."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":315190000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125801,"accession_number":"0001104659-25-100106","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Certara refinances $296.25M term loans at lower interest rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sixth Amendment reduces margin on term loans to SOFR+2.75% or ABR+1.75%.","$296.25M Replacement Term Loans refinanced all existing term loans on Oct 16, 2025.","Expects reduced borrowing cost and interest expense savings versus prior terms.","All consenting lenders exchanged existing loans; one new lender joined.","Covenants, guarantees, and collateral terms remain substantially unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142534,"accession_number":"0001827090-25-000034","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).","Net loss improved 84% to $2.0M from $12.6M in Q2 2024.","Adjusted EBITDA $31.9M (+21% YoY); Chemaxon contributed $5.3M to revenue.","Full-year 2025 financial guidance reaffirmed, citing sustained demand for model-informed drug development.","CEO highlighted software product enhancements and new product introductions driving long-term growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":210574000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160581,"accession_number":"0001104659-25-052027","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Certara shareholders elect four Class II directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Eran Broshy (101.4M for, 44.5M withheld), Cynthia Collins (135.1M for), John Reynders (145.5M for), Matthew Walsh (131.7M for).","Ratified RSM US LLP as auditor for FY2025 with 150.4M for, 335.7K against, 83.1K abstain.","Advisory say-on-pay proposal approved with 139.1M for, 6.7M against, 81.7K abstain, 4.9M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160580,"accession_number":"0001827090-25-000026","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).","Net income $4.7M vs net loss of $4.7M in Q1 2024; adjusted EBITDA $34.8M (+20%).","Reiterated full-year 2025 financial guidance.","CEO cites FDA roadmap for reducing animal testing as opportunity for biosimulation.","CFO notes strong commercial execution despite biopharma headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":106004000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160579,"accession_number":"0001827090-25-000021","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Certara reports Q1 preliminary revenue up 10% to $106M; $100M buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 revenue $106.0M (+10% YoY); software revenue $46.4M (+18%), services $59.6M (+4%).","Bookings of $118.0M (+12% YoY); software bookings $40.6M (+22%), services bookings $77.4M (+7%).","Adjusted EBITDA estimated $33-$35M (13-20% growth); FY 2025 guidance reaffirmed: rev $415-$425M, adj EPS $0.42-$0.46.","Board authorized $100M share repurchase program; Arsenal Capital agrees to one-year lock-up on shares acquired from EQT.","Regulatory services strategic review ongoing; discussions with external parties remain preliminary."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":106004000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178826,"accession_number":"0001827090-25-000018","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Certara President Patrick F. Smith steps down, moves to senior advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025.","Smith remains employed at Certara in a senior advisory and scientific capacity.","No replacement for the President role was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178825,"accession_number":"0001827090-25-000012","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q4 revenue +14% to $100.4M; net income turns positive; guides 2025 margins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $100.4M (+14% YoY); software rev $42.3M (+26%), services $58.1M (+7%).","Net income $6.6M vs net loss $12.5M in Q4 2023; adjusted EBITDA $33.5M (+13%).","Chemaxon contributed $6.6M revenue in Q4, ahead of expectations.","FY 2025 guidance: adj. EBITDA margins in low thirties; end markets similar to 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":385148000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178824,"accession_number":"0001827090-25-000003","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara reports preliminary Q4 revenue $99.7M (+13% YoY); FY revenue $384.4M (+8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $99.7M vs $88.0M YoY; software +24% to $41.6M, services +7% to $58.1M.","FY 2024 revenue $384.4M vs $354.3M; software +18% to $155.0M, services +3% to $229.4M.","Full-year bookings $445.3M (+11% YoY); adjusted EBITDA guidance reaffirmed at $120M-$124M.","Q4 bookings $144.5M (+22% YoY); included Chemaxon contribution of $5.9M revenue and $11.0M bookings.","Chemaxon acquisition closed Oct 1, 2024; prelim results are unaudited and subject to finalization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":385148000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195497,"accession_number":"0001827090-24-000035","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 rev $94.8M (+11% YoY); net loss narrows to $1.4M; guides FY24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $94.8M (+11% YoY); software rev $35.9M (+15%), services rev $58.9M (+9%).","Net loss $1.4M vs $49.0M loss in Q3 2023; improvement driven by lower goodwill impairment.","Adjusted EBITDA $33.1M, up 15% from $28.8M in Q3 2023.","CEO cites Chemaxon acquisition closed; focus on integrating biosimulation platform.","Full-year 2024 financial guidance updated (specifics not provided in release snippet)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":284787000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195496,"accession_number":"0001104659-24-109235","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints Dr. John V. W. Reynders to Board of Directors, effective Oct 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Reynders appointed as Class II director and Audit Committee member, effective immediately.","Board size increased from 9 to 10 directors.","Compensation per non-employee director policy; standard indemnification agreement to be entered.","No family relationships or transactions with officers/directors requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211759,"accession_number":"0001827090-24-000028","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 2024 revenue $93.3M (+3% YoY); net loss $12.6M vs profit prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $93.3M, up 3% YoY; software revenue $38.2M (+13%), services revenue $55.1M (-3%).","Net loss $12.6M compared to net income $4.7M in Q2 2023; adjusted EBITDA $26.3M vs $32.4M prior year.","Company reiterates full-year 2024 financial guidance.","CEO cites strong software performance offset by slowing large biopharma services demand."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":189967000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211758,"accession_number":"0001104659-24-081169","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Certara amends bylaws to remove former majority stockholder provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On July 17, 2024, Board approved amended and restated Bylaws, effective same day.","Changes remove inoperative provisions related to former majority stockholder.","Certificate of Incorporation similarly amended; stockholder approval on May 23, 2024.","Full text of Bylaws filed as Exhibit 3.2, marked changes as Exhibit 3.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211757,"accession_number":"0001104659-24-078581","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.","Transaction expected to close in H2 2024, subject to regulatory approval and customary conditions.","Chemaxon expected to generate >$20M software revenue in 2024; adjusted EBITDA margin near Certara's corporate average by end 2025.","Certara reiterates 2024 revenue, adjusted EBITDA margin (31-33%), and adjusted diluted EPS guidance from May 7 earnings call.","Acquisition expands Certara's drug discovery biosimulation portfolio; long-term partnership with Chemaxon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230508,"accession_number":"0001104659-24-075179","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Certara refinances credit facility; extends term loan maturity to 2031, revolver to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total new term loans of $300M (including $5M incremental) refinance existing debt and fund general corporate purposes.","Term loan maturity extended to June 26, 2031; revolving facility maturity extended to June 26, 2029.","Pricing reduced: Term SOFR + 3.00% for term loans; revolver spread 2.75%-3.50% based on leverage.","New term loans funded at 99.75% of par (0.25% original issue discount).","Company expects interest expense savings compared to prior credit agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230507,"accession_number":"0001827090-24-000018","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Certara shareholders elect directors, approve charter amendments, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors: Cashman (97.7M for), Killefer (116.4M), Spaight (134.1M); all supported.","Approved charter amendment to limit officer liability (121.99M for, 17.85M against).","Approved technical charter amendments (139.78M for, 62.6K against).","Ratified Ernst & Young as auditor for FY2024 (143.94M for).","Advisory vote on executive compensation passed (132.6M for, 7.23M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230506,"accession_number":"0001827090-24-000011","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 revenue $96.7M +7% YoY; net loss $4.7M, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $96.7M (+7% YoY); software rev $39.3M (+19%), services $57.3M (flat).","Net loss $4.7M vs net income $1.4M in Q1 2023; adjusted EBITDA $29.1M down from $32.3M.","Software net retention ratio 114%.","Reiterated full year 2024 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":96654000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}